LENZ
Price
$38.15
Change
+$0.78 (+2.09%)
Updated
Aug 28, 04:59 PM (EDT)
Capitalization
1.09B
SLXN
Price
$7.74
Change
+$0.48 (+6.61%)
Updated
Aug 28, 04:59 PM (EDT)
Capitalization
5.66M
Interact to see
Advertisement

LENZ vs SLXN

Header iconLENZ vs SLXN Comparison
Open Charts LENZ vs SLXNBanner chart's image
LENZ Therapeutics
Price$38.15
Change+$0.78 (+2.09%)
Volume$4.83K
Capitalization1.09B
Silexion Therapeutics
Price$7.74
Change+$0.48 (+6.61%)
Volume$300
Capitalization5.66M
LENZ vs SLXN Comparison Chart in %
Loading...
LENZ
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SLXN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
LENZ vs. SLXN commentary
Aug 29, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is LENZ is a StrongBuy and SLXN is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 29, 2025
Stock price -- (LENZ: $38.20 vs. SLXN: $7.74)
Brand notoriety: LENZ and SLXN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: LENZ: 56% vs. SLXN: 35%
Market capitalization -- LENZ: $1.09B vs. SLXN: $5.66M
LENZ [@Biotechnology] is valued at $1.09B. SLXN’s [@Biotechnology] market capitalization is $5.66M. The market cap for tickers in the [@Biotechnology] industry ranges from $100.52B to $0. The average market capitalization across the [@Biotechnology] industry is $1.84B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

LENZ’s FA Score shows that 1 FA rating(s) are green whileSLXN’s FA Score has 0 green FA rating(s).

  • LENZ’s FA Score: 1 green, 4 red.
  • SLXN’s FA Score: 0 green, 5 red.
According to our system of comparison, LENZ is a better buy in the long-term than SLXN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

LENZ’s TA Score shows that 4 TA indicator(s) are bullish while SLXN’s TA Score has 5 bullish TA indicator(s).

  • LENZ’s TA Score: 4 bullish, 6 bearish.
  • SLXN’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, SLXN is a better buy in the short-term than LENZ.

Price Growth

LENZ (@Biotechnology) experienced а -4.14% price change this week, while SLXN (@Biotechnology) price change was +13.75% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.11%. For the same industry, the average monthly price growth was +20.33%, and the average quarterly price growth was +29.99%.

Industries' Descriptions

@Biotechnology (+2.11% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
LENZ($1.09B) has a higher market cap than SLXN($5.66M). LENZ YTD gains are higher at: 32.317 vs. SLXN (-74.345). SLXN has higher annual earnings (EBITDA): -17.81M vs. LENZ (-61.87M). LENZ has more cash in the bank: 210M vs. SLXN (3.47M). LENZ has less debt than SLXN: LENZ (1.05M) vs SLXN (3.7M). LENZ has higher revenues than SLXN: LENZ (5M) vs SLXN (0).
LENZSLXNLENZ / SLXN
Capitalization1.09B5.66M19,261%
EBITDA-61.87M-17.81M347%
Gain YTD32.317-74.345-43%
P/E Ratio48.03N/A-
Revenue5M0-
Total Cash210M3.47M6,059%
Total Debt1.05M3.7M28%
TECHNICAL ANALYSIS
Technical Analysis
LENZSLXN
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
64%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
76%
Bearish Trend 1 day ago
10%
Momentum
ODDS (%)
Bearish Trend 2 days ago
78%
Bullish Trend 1 day ago
27%
MACD
ODDS (%)
Bullish Trend 2 days ago
85%
Bullish Trend 1 day ago
30%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
82%
Bullish Trend 1 day ago
27%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
87%
Bearish Trend 1 day ago
52%
Advances
ODDS (%)
Bullish Trend 7 days ago
83%
Bullish Trend 1 day ago
53%
Declines
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 8 days ago
76%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
78%
Bullish Trend 4 days ago
38%
Aroon
ODDS (%)
Bearish Trend 2 days ago
83%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
LENZ
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SLXN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
PLBEX32.69N/A
N/A
Plumb Equity Investor
FMSTX34.70N/A
N/A
Federated Hermes MDT Large Cap Value IS
SMFYX42.62N/A
N/A
American Beacon Stephens Mid-Cap Gr Y
LGLSX54.16N/A
N/A
Lord Abbett Growth Leaders R4
DIVHX29.38N/A
N/A
Cutler Equity Fund